Market Overview:
The global granulocyte-colony stimulating factor (G-CSF) drugs market is expected to register a CAGR of 7.8% during the forecast period, 2018–2030. The growth in the market can be attributed to factors such as increasing incidence of cancer and blood diseases, rising demand for G-CSF drugs for indications such as oncology and blood diseases, and growing number of approvals for G-CSF drugs by regulatory authorities across the globe. Based on type, the global G-CSF drugs market is segmented into filgrastim, pefigrastim, and lipefigrastim. Filgrastim held a dominant position in 2017 and is expected to maintain its dominance throughout the forecast period. This can be attributed to its high usage rates across indications such as cancer and blood diseases. Pefigrastim accounted for a significant share of the global G-CSF drugs market in 2017 owing to its high adoption rates in countries such as Japan and South Korea. Lipefigrastim is projected to grow at a higher CAGR during the forecast period due to increasing adoption rates in developed countries such as Germany, France, Italy Spain), etc.
 Drugs Industry Outlook.svg)
Product Definition:
Granulocyte-Colony Stimulating Factor (G-CSF) is a glycoprotein that is produced by the myeloid stem cells in the bone marrow. It stimulates the proliferation and differentiation of neutrophils, erythrocytes, and platelets. G-CSF is used to increase white blood cell counts in patients who have undergone chemotherapy or radiation therapy, to prevent or treat infection in neutropenic patients, and to stimulate platelet production for those receiving hematopoietic stem cell transplants.
Filgrastim:
Filgrastim is a type of interleukin (IL) that promotes the growth and proliferation of granulocytes. Interleukins are proteins belonging to the family of cytokines which are produced by certain types of white blood cells in response to foreign substances such as bacteria, viruses or tumor cells. Filgrastim is approved for treatment for chronic myeloid leukemia, but it has also been used in other diseases including rheumatoid arthritis and multiple sclerosis.
Pefigrastim:
Pefigrastim is a pegylated version of the human growth hormone, which is also known as pituitary growth hormone. It is currently in phase II clinical trials and has been tested to have an efficacy similar to that of current G-CSF drugs. The drug was found to be well tolerated with no major side effects at doses up to 1 mg/kg every 8 hours.
Application Insights:
Oncology was the largest revenue-generating segment in 2017. This is owing to the high prevalence of cancer worldwide, which results in a growing need for G-CSF drugs. According to data published by WHO, it has been estimated that around 9 out of 10 deaths occur in low and middle-income countries due to cancer. In addition, as per the American Cancer Society, around 1 million new cases of cancer are reported every year globally with about 90% of these cases occurring in developing countries. Therefore, a significant number of patients suffering from malignant diseases require G-CSF therapy for complete recovery and effective treatment outcomes.
The other application segment includes rheumatoid arthritis.
Regional Analysis:
North America dominated the global G-CSF market in 2016 with a revenue share of over 40%. Key factors contributing to its large share include the presence of key players, high adoption rate for novel therapeutics, and favorable reimbursement policies. The U.S. is one of the largest markets for cancer drugs due to various initiatives undertaken by government & private organizations that focus on increasing cancer incidence rates in this country so as to improve healthcare expenditure ratio and reduce mortality rate from cancer.
Asia Pacific is expected to be fastest growing region during the forecast period owing to rising incidences of blood diseases such as leukemia & lymphoma coupled with an increase in stem cell transplantation procedures across emerging countries such as China & India which are also among top 10 countries regarding population size worldwide (1). Moreover, Asia Pacific has a huge base of geriatric population that requires long term care medication thereby creating lucrative growth opportunities for G-CSF drug manufacturers over next eight years (2).
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is one of the major growth drivers for the G-CSF drugs market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in the U.S. in 2017 and around 600,920 people will die from this disease. This growing prevalence of cancer is expected to drive demand for G-CSF drugs in order to improve patient outcomes.
- Rising geriatric population: The global geriatric population is growing at a rapid pace and this is expected to drive demand for G-CSF drugs over the forecast period. Elderly patients are more susceptible to various types of infections and diseases due to their weakened immune system, which can lead to poor prognosis and increased mortality rates post treatment with G-CSF drugs therapy .Thus, rising geriatric population is anticipated to boost growth prospects for the global G-CSF drugs market during the forecast period .
Scope Of The Report
Report Attributes
Report Details
Report Title
Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Research Report
By Type
Filgrastim, Pefigrastim, Lipefigrastim
By Application
Oncology, Blood Disease, Other
By Companies
Amgen, Kyowa Kirin, Chugai Pharmaceutical, Novartis, Teva, Pfizer, Merck, Dong-A Socio, Intas, GenSci, Dr. Reddy, Amoytop, North China Pharmaceutical, SL Pharm, Hayao Group
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
228
Number of Tables & Figures
160
Customization Available
Yes, the report can be customized as per your need.
Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Report Segments:
The global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market is segmented on the basis of:
Types
Filgrastim, Pefigrastim, Lipefigrastim
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Oncology, Blood Disease, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amgen
- Kyowa Kirin
- Chugai Pharmaceutical
- Novartis
- Teva
- Pfizer
- Merck
- Dong-A Socio
- Intas
- GenSci
- Dr. Reddy
- Amoytop
- North China Pharmaceutical
- SL Pharm
- Hayao Group
 Drugs Market Overview.svg)
Highlights of The Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Filgrastim
- Pefigrastim
- Lipefigrastim
- By Application:
- Oncology
- Blood Disease
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Drugs Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Granulocyte-Colony Stimulating Factor (G-CSF) drugs are medications that help to increase the number of granulocytes in the blood. Granulocytes are cells that play a role in fighting infection.
Some of the key players operating in the granulocyte-colony stimulating factor (g-csf) drugs market are Amgen, Kyowa Kirin, Chugai Pharmaceutical, Novartis, Teva, Pfizer, Merck, Dong-A Socio, Intas, GenSci, Dr. Reddy, Amoytop, North China Pharmaceutical, SL Pharm, Hayao Group.
The granulocyte-colony stimulating factor (g-csf) drugs market is expected to register a CAGR of 7.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size & Forecast, 2018-2028
4.5.1 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size and Y-o-Y Growth
4.5.2 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Absolute $ Opportunity
Chapter 5 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Forecast by Type
5.2.1 Filgrastim
5.2.2 Pefigrastim
5.2.3 Lipefigrastim
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Forecast by Applications
6.2.1 Oncology
6.2.2 Blood Disease
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Forecast by Type
9.6.1 Filgrastim
9.6.2 Pefigrastim
9.6.3 Lipefigrastim
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Forecast by Applications
9.10.1 Oncology
9.10.2 Blood Disease
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Forecast by Type
10.6.1 Filgrastim
10.6.2 Pefigrastim
10.6.3 Lipefigrastim
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Forecast by Applications
10.10.1 Oncology
10.10.2 Blood Disease
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Forecast by Type
11.6.1 Filgrastim
11.6.2 Pefigrastim
11.6.3 Lipefigrastim
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Forecast by Applications
11.10.1 Oncology
11.10.2 Blood Disease
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Forecast by Type
12.6.1 Filgrastim
12.6.2 Pefigrastim
12.6.3 Lipefigrastim
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Forecast by Applications
12.10.1 Oncology
12.10.2 Blood Disease
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Forecast by Type
13.6.1 Filgrastim
13.6.2 Pefigrastim
13.6.3 Lipefigrastim
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Forecast by Applications
13.10.1 Oncology
13.10.2 Blood Disease
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market: Competitive Dashboard
14.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Amgen
14.3.2 Kyowa Kirin
14.3.3 Chugai Pharmaceutical
14.3.4 Novartis
14.3.5 Teva
14.3.6 Pfizer
14.3.7 Merck
14.3.8 Dong-A Socio
14.3.9 Intas
14.3.10 GenSci
14.3.11 Dr. Reddy
14.3.12 Amoytop
14.3.13 North China Pharmaceutical
14.3.14 SL Pharm
14.3.15 Hayao Group
